Foresee Pharmaceuticals has shown that a long-acting version of its injectable prostate cancer med Camcevi can help patients ...

Ultragenyx Pharmaceutical has reported the failure of a pair of late-phase brittle bone disease trials, prompting the biotech to prepare to significantly reduce its spending.

The financing uses a single-asset SPV, allowing BioAtla to fund a pivotal study without a broader equity raise. ・BioAtla ...

Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...

Ambros Therapeutics launches with $125M to advance neridronate, a non-opioid therapy for CRPS-1. See how this Phase 3-ready ...

Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure ...

The company was aiming for approval in the second half of 2028, paving the way for a market launch in 2029 Hangzhou-based ...

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily oral peptide—has passed a phase 3 checkpoint with results that could pad ...

The U.S. Space Force has selected SpaceX and United Launch Alliance to perform the first seven launches under the National Security Space Launch Program, or NSSL, Phase 3 Lane 2 contracts, Breaking ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The study, Step-Up HS, will evaluate Rinvoq ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Use of alternative endpoints in phase 3 oncology trials ...

OICL Assistant RLT Admit Card 2026 has been released for Phase 3. Candidates can download the Regional Language Test call ...